Im ready to get started Check your eligibility in minutes Answer a few quick questions to see if you qualify for our GLP-1 programs Secure
Both semaglutide and tirzepatide reduce insulin resistance and improve insulin sensitivity, critical for patients managing excess weight, blood sugar, and metabolic-associated liver disease
The Verdict: For health-conscious adults whose anti-aging goals center on physical resilience, joint health, and injury recovery, BPC-157 offers a mechanistically compelling (if not yet human-validated) toolkit
The full human evidence base for BPC-157: One IV safety pilot in two adults One chart review of 16 knee-pain patients, no control One chart review of 12 interstitial cystitis patients, no control One Phase I trial registered in 2015, then cancelled with no published results A Phase II hamstring-strain trial registered, no results yet That is the entire dataset